New research examined the effects of cataract surgery on visual acuity and disease activity in patients with nAMD receiving anti-VEGF treatment. The treatment intensity for underlying nAMD remained ...

A deep learning model may be able to outperform ophthalmologists in predicting neovascular age-related macular degeneration (nAMD) recurrence. Recurrence of neovascular age-related macular ...

BARCELONA, Spain — Patients who receive a diagnosis of neovascular age-related macular degeneration (nAMD) from their primary care clinician may be less likely to adhere to treatment than those who ...

Please provide your email address to receive an email when new articles are posted on . Age-related macular degeneration (AMD) is the fourth most common cause of blindness globally and the leading ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The high number of clinical visits needed to monitor and ...

P041, an aflibercept biosimilar, showed noninferiority to originator aflibercept (Eylea) in maintaining vision in nAMD patients over 52 weeks. The study involved 168 patients, with 145 completing the ...

Roche (RHHBY) announced new data from two studies on ophthalmology drug Vabysmo (faricimab). Vabysmo is already approved in several countries for people with neovascular or ‘wet’ age-related macular ...

Faricimab is the first bispecific antibody that binds to both Ang-2 and VEGF-A This article is part of MPR’s coverage of the American Academy of Ophthalmology 2019 Meeting, taking place in San ...

The study examined patients who were treated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) compounds for their nAMD. A total of 76 patients (92 eyes) were followed for at least ...

NEW YORK (Reuters Health) - The investigational drug abicipar pegol is noninferior to ranibizumab for achieving stable vision in people with neovascular age-related macular degeneration (nAMD), ...

Company to present topline 40-week Phase 2 study efficacy and safety results of migaldendranib (MGB), a novel first-in-class nanomedicine for DME and nAMD Subcutaneous at-home administration ...